A New York Times article published today makes the scandalous revelation that SmithKline Beecham (now called GlaxoSmithKline) conducted a study on its new diabetes drug, Avandia, in 1999, and has been working to hide the findings from the public for the past 11 years.
The 1999 study found that Avandia was not only no more effective than its competitor, Actos, but also that it presented more risks of heart attack and stroke. The Times published the following excerpt from an email written in 2001 by SmithKline executive Dr. Martin I. Freed:
"This was done for the U.S. business, way under the radar. Per Sr. Mgmt request, these data should not see the light of day to anyone outside of GSK."
To make matters worse, it seems that Dr. John Jenkins, head of the F.D.A.'s office of new drugs, has been rooting for Avandia, speaking out against taking it off the market, and "disciplining" an employee who recommended that the health warnings be strengthened for Avandia.
No comments:
Post a Comment